Clinical trial data of Apelix

The data in clinical trials of Alpelisib (Alpelisib) mainly involve its application in the treatment of breast cancer. Clinical trial data show that apelvis, as a PI3K inhibitor, has a certain effect on hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer carrying PIK3CA gene mutations. For example, in the SOLAR-1 clinical trial, apelvis combined with an aromatase inhibitor significantly prolonged progression-free survival compared with the aromatase inhibitor alone. Data from these trials support the effectiveness of apelvis in selected patients with breast cancer and provide a rationale for its use in clinical practice. However, specific clinical trial data may update over time, so it is recommended to review the latest research literature or consult a medical professional for the most up-to-date information.